Biogen Inc. NMS · BIIB

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

GlobeNewswire Inc. · 7d ago

Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida

GlobeNewswire Inc. · 16d ago

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

The Motley Fool · 18d ago

Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

GlobeNewswire Inc. · 23d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

GlobeNewswire Inc. · 29d ago

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

GlobeNewswire Inc. · 30d ago

Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

Benzinga · 34d ago

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

GlobeNewswire Inc. · 34d ago

Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish

Investing.com · 61d ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

GlobeNewswire Inc. · 62d ago

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

GlobeNewswire Inc. · 64d ago

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

GlobeNewswire Inc. · 65d ago

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

GlobeNewswire Inc. · 69d ago

Dow Jones Rally Looks Fragile With Inflation Data Running Hot

Investing.com · 69d ago

Why Is Biogen Stock Falling Thursday?

Benzinga · 69d ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

Benzinga · 69d ago

Lecanemab Injection Market Report 2026: Increasing Adoption of Monoclonal Antibody Therapies and Rising Focus on Early Alzheimer's Intervention - Global Long-term Forecasts to 2030 and 2035

GlobeNewswire Inc. · 72d ago

Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy

Benzinga · 75d ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

GlobeNewswire Inc. · 75d ago

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

GlobeNewswire Inc. · 84d ago

This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?

The Motley Fool · 97d ago

Administrator Loeffler Applauds SBIR-STTR Reauthorization

GlobeNewswire Inc. · 99d ago

Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034

GlobeNewswire Inc. · 100d ago

Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward

Benzinga · 106d ago

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

GlobeNewswire Inc. · 107d ago